Skip to content

Fighting to Preserve the Benefits of the 340B Program

Facebook page opens in new windowX page opens in new windowLinkedin page opens in new windowMail page opens in new window
RWC-340B
Ryan White Clinics for 340B Access
RWC-340B
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • Get The Facts
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
  • News
  • About Us
    • RWC-340B Principles
Search:
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • Get The Facts
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
  • News
  • About Us
    • RWC-340B Principles

J&J Sues HHS and HRSA Over HRSA’s Opposition to J&J’s Proposed Rebate Model

Drug Pricing, HHS, HRSA, News, RWC-340BBy Amber TynanNovember 20, 2024

11/14/2024 – J&J Sues HHS and HRSA Over HRSA’s Opposition to J&J’s Proposed Rebate Model On November 12, 2024, Johnson and Johnson Health Care System Inc. (J&J) filed a lawsuit…

HHS Issues Revised ADR Regulations

HHS, HRSA, Regulations, RWC-340BBy Amber TynanApril 18, 2024

Today, HHS published revised 340B administrative dispute resolution regulations (ADR Rule) that will replace existing ADR regulations effective June 18.   Most notably, the ADR Rule does not include a proposal…

Gilead Expands Claims Submission Requirements to Wholly-Owned Contract Pharmacies; Government Declines to Appeal Genesis Patient Definition Decision; Egwim Steps Down as Director of OPA.

HHS, News, Regulations, RulingsBy Amber TynanJanuary 8, 2024

Gilead Expanded Policy Gilead expanded its existing restrictions on contract pharmacy arrangements, effective January 30, 2024, but only for covered entities that dispense 340B drugs through wholly-owned contract pharmacies.  Gilead’s…

Gilead

RWC-340B Sends Letters to Gilead, HHS Secretary, and OPA Director.

Congress, Drug Pricing, HHS, HRSA, Regulations, RWC-340BBy Amber TynanApril 15, 2022

A growing number of pharmaceutical manufacturers have recently posed restrictions affecting Ryan White Clinics and other Safety Net Providers. RWC-340B has taken action to address these challenges head-on.   On…

Spanberger

Spanberger to HHS: Hold Drug Companies Accountable for Breaking the Law, Crack Down on Illegal Price Hikes

Drug Pricing, HHS, NewsBy Amber TynanJanuary 26, 2022

In response to a rash of reckless decisions by pharmaceutical companies, U.S. Representative Abigail Spanberger is leading a bipartisan effort to protect the 340B Drug Pricing Program and prevent additional…

volodymyr hryshchenko m1Hq4ibP9rc unsplash

New AbbVie and Lilly Contract Pharmacy Policies

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaJanuary 6, 2022

AbbVie is the 11th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies By letter dated December 29, 2021, AbbVie announced that, effective February 1, 2022, it will implement…

glsun guilin WNX6uk 1LV4 unsplash

UCB Latest Manufacturer to Announce Restrictive Contract Pharmacy Policy; HRSA Issues Statement Regarding Manufacturer Lawsuits

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaNovember 23, 2021

By letter dated November 22, 2021, drug manufacturer UCB, Inc. notified covered entities that it is “altering its 340B policy” and will no longer honor contract pharmacy arrangements, effective December…

courthouse g329b35186 1280

Update on 340B Contract Pharmacy Litigation — Decisions Issued in Four Manufacturer Lawsuits

Drug Pricing, HHS, HRSA, News, RulingsBy Andrea JeriaNovember 8, 2021

On Friday, November 5, two federal courts issued decisions in four of the lawsuits that drug manufacturers filed against HHS challenging HHS’ May 17 cease-and-desist letters (“May 17 Letters”) notifying…

RWC 340B Logo hi res

RWC-340B Applauds Court’s “Fairest and Most Reasonable” Interpretation of the 340B Drug Pricing Program: Manufacturer Actions Shall Not Undermine the Safety Net

Drug Pricing, HHS, HRSA, News, RWC-340BBy Andrea JeriaNovember 2, 2021

PRESS STATEMENT: FOR IMMEDIATE RELEASE         Contact: Peggy.Tighe@PowersLaw.com RWC-340B Applauds Court’s “Fairest and Most Reasonable” Interpretation of the 340B Drug Pricing Program:  Manufacturer Actions Shall Not Undermine the Safety Net…

index

Indiana Federal Court Issues Decision in Eli Lilly’s Contract Pharmacy Lawsuit

Drug Pricing, HHS, HRSA, News, Rulings, RWC-340BBy Andrea JeriaNovember 1, 2021

On Friday, the U.S. District Court for the Southern District of Indiana (the Court) issued a decision supporting HRSA’s statutory interpretation, as reflected in HRSA’s May 17 determination, that Eli…

→12345…
6
7→
                                                                            © 2021 Ryan White Clinics for 340B Access. RWC-340B is a 501(c)(4) non-profit corporation.
Go to Top
Translate »
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset